Lipids & metabolic liver disease
Prospective associations of triglyceride-glucose related indices with cardiovascular disease and mortality in individuals with metabolic syndrome: evidence from the UK biobank
Main finding · Total CVD (TyG-WC)Result — go to the resultHazard ratio 1.42 95% CI 1.36–1.48Authors' conclusion
TyG-BMI, TyG-WC, and TyG-WHtR were robust predictors of CVD and mortality in individuals with MetS. These indices exhibited nonlinear threshold effects and improved predictive performance, supporting their utility in clinical risk stratification.
Study context
- Population
- UK Biobank participants with metabolic syndrome (MetS) free of cardiovascular disease (CVD) at baseline
- Participants
- 113,699 participants
- Exposure
- Highest vs lowest quartile of triglyceride-glucose (TyG)-related indices
- Outcome
- CVD and mortality outcomes
- Follow-up
- Median 13.7 years
Methodological detailslarge-scale, UK Biobank, quartile analysis
- Large-scale
- UK Biobank
- Quartile analysis
Main finding
Total CVD (TyG-WC)
Hazard ratio
1.42
95% CI 1.36–1.48
Highest quartilevs Lowest quartile
HR 1.42 (95% CI 1.36–1.48)
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | HR (CI) | |
|---|---|---|
| CVD mortality (TyG-WC)TyG-WC | 1.51 (1.32–1.72) | |
| 0.512Hazard ratio (log scale) |
Dose-response
- Linear association with coronary heart disease (CHD); U- or J-shaped nonlinear relationships for other CVD outcomes, risks rising beyond inflection points
Incremental predictive value (net reclassification index (NRI), integrated discrimination improvement (IDI))
- TyG-waist circumference (TyG-WC) greatest for total CVD, all-cause mortality and CVD mortality; TyG-waist-to-height ratio (TyG-WHtR) largest for CHD and stroke
Trajectory analyses
- Persistently high TyG-related trajectories had substantially elevated CVD risks
Original publication
Prospective associations of triglyceride-glucose related indices with cardiovascular disease and mortality in individuals with metabolic syndrome: evidence from the UK biobank. Cardiovasc Diabetol. Published 21 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →